MGAM
MDGL icon

McGowan Group Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

McGowan Group Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$262K – 164
2026
Q1 		$262K Buy
+500
New +$239K 0.03% 114

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

McGowan Group Asset Management's MDGL Position: Q2 2026 in Review

McGowan Group Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 500 shares — an estimated $262K sold.

McGowan Group Asset Management first reported a position in MDGL in Q1 2026 and held it in 1 quarter. The position peaked at $262K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • McGowan Group Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • McGowan Group Asset Management sold 500 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $262K.
  • McGowan Group Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • McGowan Group Asset Management's Madrigal Pharmaceuticals position peaked at $262K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on McGowan Group Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.